These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2508213)

  • 1. Protective effect of low dose of enprostil against gastric blood loss induced by aspirin in man.
    Thiefin G; Fierfort E; Duchateau A; Garbe E; Joubert M; Zeitoun P
    Scand J Gastroenterol; 1989 Sep; 24(7):827-32. PubMed ID: 2508213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction by enprostil of aspirin-induced blood loss from human gastric mucosa.
    Hawkey CJ; Simpson G; Somerville KW
    Am J Med; 1986 Aug; 81(2A):50-3. PubMed ID: 3092655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of enprostil against aspirin-induced gastroduodenal mucosal injury in man. Comparison with cimetidine and sucralfate.
    Stiel D; Ellard KT; Hills LJ; Brooks PM
    Am J Med; 1986 Aug; 81(2A):54-8. PubMed ID: 3092656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory action of enprostil (4,5-dehydro-16-phenoxy-17,18,19,20-tetranor-PGE2) on tetra-gastrin stimulated acid secretion in human subjects.
    Moriga M; Aono M; Narusawa H; Kohli Y; Kato T; Kajiyama G; Inoue M; Miyoshi A
    Gastroenterol Jpn; 1989 Apr; 24(2):115-9. PubMed ID: 2501133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specificity of PGE2 analogs interaction between food intake and antisecretory effect.
    Levine RA; Petokas S; Czarny L; Schwartz GJ; Bynum L
    Prostaglandins Leukot Med; 1986 Oct; 24(2-3):219-25. PubMed ID: 3099313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enprostil, a synthetic prostaglandin E2 analogue, inhibits meal-stimulated gastric acid secretion and gastrin release in patients with duodenal ulcer.
    Thomas FJ; Koss MA; Hogan DL; Isenberg JI
    Am J Med; 1986 Aug; 81(2A):44-9. PubMed ID: 3092654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against aspirin-induced antral and duodenal damage with enprostil. A double-blind endoscopic study.
    Cohen MM; McCready DR; Clark L; Sevelius H
    Gastroenterology; 1985 Jan; 88(1 Pt 2):382-6. PubMed ID: 3917264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a single oral dose of enprostil on gastric secretion and gastrin release. Studies in healthy volunteers and patients with pernicious anemia.
    Buchanan N; Laferla G; Hearns J; Buchanan KD; Crean GP; McColl KE
    Am J Med; 1986 Aug; 81(2A):40-3. PubMed ID: 3092653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for preventing aspirin-induced gastric bleeding.
    Hawkey CJ; Prichard PJ; Somerville KW
    Scand J Gastroenterol Suppl; 1986; 125():170-3. PubMed ID: 3103204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisecretory and serum gastrin lowering effect of enprostil in patients with duodenal ulcer disease.
    Mahachai V; Walker K; Sevelius H; Thomson AB
    Gastroenterology; 1985 Sep; 89(3):555-61. PubMed ID: 3926591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of duodenal ulcer with enprostil, a synthetic prostaglandin E2 analogue.
    Thomson AB
    Am J Med; 1986 Aug; 81(2A):59-63. PubMed ID: 3092657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A synthetic prostaglandin E2 analogue, enprostil, hastens gastric emptying of solids in patients with an active duodenal ulcer.
    Nowak A; Jonderko K; Nowakowska-Duława E; Adamczak D; Rudzka J; Nowak S
    Scand J Gastroenterol; 1990 Nov; 25(11):1118-22. PubMed ID: 2125742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisecretory and cytoprotective doses of enprostil do not alter gastric mucosal blood flow.
    Livingston EH; Guth PH
    Life Sci; 1993; 52(20):1621-8. PubMed ID: 8483391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of two-week treatment with enprostil (35 micrograms twice a day) on 24-hour serum gastrin levels.
    Florent C; Cogoni C; Joubert M; Desaint B
    Dig Dis Sci; 1990 Nov; 35(11):1352-7. PubMed ID: 2121423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of gastric ulcer with enprostil.
    Navert H
    Am J Med; 1986 Aug; 81(2A):75-9. PubMed ID: 3092660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No abortion-inducing effect of the ulcer-healing dose of the synthetic prostaglandin E2 analogue enprostil in first trimester.
    Jacobson J; Bergquist C; Rydnert J; Bokström H; Huovinen K
    Acta Obstet Gynecol Scand; 1990; 69(2):135-8. PubMed ID: 2117332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A US multicenter study of enprostil 35 micrograms twice daily for treatment of prepyloric, pyloric channel, and duodenal bulb ulcers. Enprostil Study Group.
    Schubert TT; Frizzell JA; Meier PB; Cano RI; Schwartz KE
    Dig Dis Sci; 1989 Sep; 34(9):1355-60. PubMed ID: 2504566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enprostil. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease.
    Goa KL; Monk JP
    Drugs; 1987 Nov; 34(5):539-59. PubMed ID: 3121276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of aspirin-induced fecal blood loss with low-dose misoprostol tablets in man.
    Cohen MM; Clark L; Armstrong L; D'Souza J
    Dig Dis Sci; 1985 Jul; 30(7):605-11. PubMed ID: 3924533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative clinical trial of enprostil and ranitidine in the treatment of gastric ulcer.
    Dammann HG; Hüttemann W; Kalek HD; Rohner HG; Simon B
    Am J Med; 1986 Aug; 81(2A):80-4. PubMed ID: 3092661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.